Home

Gary S. Stetz

CIK 1532793 · Interim CEO · last filed 2026-08-21

Gary S. Stetz is an Interim CEO who has filed 25 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for HEPA, was dated Aug 21, 2026. Across all open-market trades the lifetime net is +$37.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $862.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$862.6K

Companies

4

Total Filings

25

Lifetime Open-Market Net

$37.8K

Filer Profile

Reported Address
104-110 AVENUE C
BAYONNE, NJ 07002
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Hepion Pharmaceuticals, Inc. (HEPA) Delisted Interim CEO 3,250,000 $0.08 $260.0K $100.0K 2 2026-08-21
CNTN Director 169,526 $2.30 $389.9K -$343.9K 1 2026-05-27
Canton Strategic Holdings, Inc. (THAR) Delisted Director — $4.74 — $0 1 2025-11-05
BCBP Director 54,202 $8.72 $472.6K $281.7K 20 2018-03-14

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-21 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) — $0 EDGAR
2026-08-12 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Buy (P) +2,000,000 $100.0K EDGAR
2026-05-27 CNTN Sell (S) −100,351 -$343.9K EDGAR
2026-04-27 — Buy (P) +1,250,000 $50.0K
2025-11-05 Canton Strategic Holdings, Inc. (THAR) Delisted Grant (A) — $0 EDGAR
2018-03-14 BCBP Buy (P) +500 $7.9K EDGAR
2017-10-25 BCBP Buy (P) +1,750 $25.5K EDGAR
2017-09-14 BCBP Mixed +10,000 $122.5K EDGAR
2017-06-20 BCBP Buy (P) +250 $3.9K EDGAR
2016-12-19 BCBP Buy (P) +725 $9.4K EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.